97001 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Glucagons
PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE
#302PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S)
#303Glucagon derivative and a composition comprising a long acting conjugate of the same
#304Method for continuous production of recombinant GLP-1 peptide by bacteria
#305NOVEL POLYPEPTIDE AND THERAPEUTIC USES THEREOF
#306Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin
#307Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
#308ARTIFICIAL RECOMBINANT PROTEIN FOR IMPROVING PERFORMANCE OF ACTIVE PROTEIN OR POLYPEPTIDE AND USE THEREOF
#309PEPTIDE TARGETING GIP AND GLP-2 RECEPTORS FOR TREATING BONE DISORDERS
#310GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY
#311Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
#312Acylated glucagon analogues
#313MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
#314IGG FC Variants for Veterinary Use
#315PHARMACEUTICAL COMPOSITION INCLUDING INSULIN AND GLUCAGON
#316A POLYPEPTIDE MOLECULE AND APPLICATION THEREOF
#317DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE
#318SUPRAMOLECULAR MODIFICATION OF PROTEINS
#319GIP/GLP1 co-agonist compounds
#320GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
#321Process for the manufacture of GLP-1 analogues
#322Treatment of neurological diseases
#323Interleukin-22 fusion proteins, and their pharmaceutical compositions
#324Glucagon derivatives
#325Long-acting exendin-4 and use thereof
#326Modified GIP peptide analogues
#327Fusion proteins of GLP-1 and GDF15 and conjugates thereof
#328Conjugates of fusion proteins of GLP-1 and FGF21
#329TRANSGENIC PIG ISLETS AND USES THEREOF FOR TREATING DIABETES
#330DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
#331METHOD FOR MODIFICATION OF POLYPETIDE AND USES
#332METHOD FOR PRODUCING LONG-CHAIN PEPTIDE
#333Polypeptides and analogues thereof for use in the treatment of diabetes and bone disorders
#334Dual-function protein for lipid and blood glucose regulation
#335GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
#336GLP-2 FUSION POLYPEPTIDES AND USES FOR TREATING AND PREVENTING GASTROINTESTINAL CONDITIONS
#337GLP-1 RECEPTOR ANTAGONISTS
#338METHOD OF CONJUGATION OF CYS-MABS
#339FUSION POLYPEPTIDE COMPRISING POLYPEPTIDE REGION THAT CAN BE O-GLYCOSYLATED
#340GIP PEPTIDE ANALOGUES
#341In vivo protein N-acylation
#342PHARMACEUTICAL COMPOSITION COMPRISING POLYPEPTIDE
#343Dual agonist fusion proteins
#344GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
#345Modified glucagon molecules
#346Glucagon-like peptide 1 receptor agonists and uses thereof
#347Extended recombinant polypeptides and compositions comprising same
#348FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO
#349SOLUBILITY OF GLP-1 PEPTIDE
#350Long-Acting Recombinant GLP1-Fc-CD47 Protein and Preparation and Use Thereof
#351Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
#352Acylated GLP-1/GLP-2 dual agonists
#353PROTEASE-RESISTANT LIPIDATED GLP-1 ANALOGS
#354Incretin analogs and uses thereof
#355GLP-1 analogues
#356Process for purifying semaglutide and liraglutide
#357Thioamide-modified peptides and uses thereof
#358FGF21 variant, fusion protein and application thereof
#359LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST
#360Method for producing dual function proteins and its derivatives
#361COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS
#362Method of Delivering a Centrally-Acting Peptide Derivative, and Method of Treating a Neuropsychiatric Disorder
#363Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders
#364GCGR antibody and GLP-1 fusion protein thereof, pharmaceutical composition thereof and application thereof
#365PRO-DRUG PEPTIDE WITH IMPROVED PHARMACEUTICAL PROPERTIES
#366MANUFACTURE OF GLUCAGON PEPTIDES
#367FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease
#368Multi-domain active protein for treating metabolic diseases
#369IN-SILICO METHOD FOR DESIGNING A (D)-POLYPEPTIDE LIGAND
#370Elevated intracranial pressure treatment
#371MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS
#372Solid phase synthesis of acylated peptides
#373Glucagon-like peptides
#374Process for the preparation of high purity glucagon
#375Peptide dual agonists of GIPR and GLP2R
#376Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
#377Long-acting co-agonists of the glucagon and GLP-1 receptors
#378GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAME
#379PURIFICATION OF GLUCAGON-LIKE PEPTIDE 1 ANALOGS
#380IgG Fc variants for veterinary use
#381GLP-1 analogues
#382GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
#383N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same
#384Incretin analogs and uses thereof
#385Engineered O-glycosylation in recombinant polypeptides and uses thereof
#386A PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE
#387Branched Discrete PEG Constructs
#388Process for purifying liraglutide
#389COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID
#390Glucagon-receptor selective polypeptides and methods of use thereof
#391Stabilization of glucagon by trehalose glycopolymer nanogels
#392Acylated GLP-1/GLP-2 dual agonists
#393LONG ACTING PROTEINS AND PEPTIDES AND METHODS OF MAKING AND USING THE SAME
#394Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides
#395PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
#396Artificial secretion peptides for heterologous protein production
#397Coiled coil immunoglobulin fusion proteins and compositions thereof
#398Long-acting co-agonists of the glucagon and GLP-1 receptors
#399Long-acting conjugates of GLP-2 derivatives
#400OXYNTOMODULIN PEPTIDE ANALOG FORMULATIONS
#401Chemo-enzymatic synthesis of semaglutide, liraglutide and GLP-1
#402Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
#403FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO
#404Bifunctional compounds
#405Peptide-oligourea hybrid compounds
#406Glucagon derivative and a composition comprising a long acting conjugate of the same
#407GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
#408GLP-1 polypeptide having GLP-1 receptor agonist activity and use thereof
#409Glucagon analogues
#410GLP-2 FUSION POLYPEPTIDES AND USES FOR TREATING AND PREVENTING GASTROINTESTINAL CONDITIONS
#411GENERATING HUMAN CELLS CAPABLE OF PRODUCING INSULIN IN RESPONSE TO GLUCOSE OR GLP-1
#412PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE
#413Acylated glucagon analogues
#414Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid
#415Glucagon derivatives
#416Peptide compound
#417Double-acylated GLP-1 derivatives
#418Glucagon/GLP-1 agonists for the treatment of obesity
#419GLP-1 ANALOG FUSION PROTEIN AND PREPARATION METHOD AND APPLICATION THEREOF
#420Long-acting GIP peptide analogues
#421Acylated glucagon analogue
#422Double-acylated GLP-1 derivatives
#423PROTEASE-RESISTANT LIPIDATED GLP-1 ANALOGS
#424Treatment of neurological diseases
#425Synthesis of liraglutide
#426In vivo protein N-acylation
#427Suspension formulation comprising an insulinotropic peptide
#428GIP/GLP1 co-agonist compounds
#429EXPRESSION AND LARGE-SCALE PRODUCTION OF PEPTIDES
#430Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same
#431Method for preparation of peptides with psWang linker
#432Protein and protein conjugate for diabetes treatment, and applications thereof
#433Mating Factor Alpha Pro-Peptide Variants
#434Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
#435Peptide dual agonists of GIPR and GLP2R
#436METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
#437Multivalent heteromultimer scaffold design and constructs
#438Acylated GLP-1/GLP-2 dual agonists
#439Method for preparing liraglutide intermediate polypeptide
#440EXPRESSION CONSTRUCT AND METHOD FOR PRODUCING PROTEINS OF INTEREST
#441GLP-1/GLP-2 dual agonists
#442Long-acting co-agonists of the glucagon and GLP-1 receptors
#443Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
#444GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
#445Method for cleavage of solid phase-bound peptides from the solid phase
#446Capping of unprotected amino groups during peptide synthesis
#447High-activity long-acting hypoglycemic fusion protein as well as preparation method and medical application thereof
#448Dual cistronic bacterial expression system
#449GLP-1 analogues
#450Glucagon analogs and methods of use thereof
#451AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
#452Thiol-yne based peptide stapling and uses thereof
#453COMBINATION
#454Therapeutic for the prevention and/or treatment of weight gain and/or diabetes
#455Glucagon-GLP-1-GIP triple agonist compounds
#456Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin Fc region
#457PROCESS FOR PREPARATION OF PROTEIN OR PEPTIDE
#458DCHBS-active esters of PEG compounds and their use
#459Fusion protein for treating intestinal diseases
#460ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE
#461GIP-GLP-1 dual agonist compounds and methods
#462Triple glucagon/GLP-1/GIP receptor agonist
#463Aqueously soluble and chemically stable glucagon peptides
#464Synthesis method for liraglutide with low racemate impurity
#465TRI-AGONIST FOR THE GLu, GLP-1 AND NPY2 RECEPTORS
#466Modified glucagon molecules
#467SOLID PHASE PEPTIDE SYNTHESIS
#468Regulated biocircuit systems
#469Glucagon and GLP-1 co-agonists for the treatment of obesity
#470SYNTHESIS OF GLP-1 PEPTIDES
#471Amino diacids containing peptide modifiers
#472Pharmaceutical Compositions
#473Methods to Treat Diseases with Protein, Peptide and Antigen Modification
#474Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
#475Generating targeted sequence diversity in fusion proteins
#476Fusion proteins of superfolder green fluorescent protein and use thereof
#477Insulin receptor partial agonists and GLP-1 analogues
#478COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS
#479GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS
#480Multivalent heteromultimer scaffold design and constructs
#481Glucagon/GLP-1 receptor co-agonists
#482Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
#483Purification of glucagon-like peptide 1 analogs
#484Method for preparing glucagon-like peptides
#485ANTI-PCSK9-GLP-1 FUSIONS AND METHODS FOR USE
#486Thiol-ene based peptide stapling and uses thereof
#487Methods of increasing nutrient absorption in the intestine using therapeutic agents comprising GLP-2 and elastin-like peptides
#488Glucagon-like peptide 1 receptor agonists and uses thereof
#489Polypeptides and analogues thereof for use in the treatment of diabetes and bone disorders
#490Method of stabilizing a bioactive peptide against protease hydrolysis
#491FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME
#492ACYLATED GLUCAGON ANALOGUES
#493Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
#494Glucagon analogues
#495NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME
#496Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
#497GLP-1 derivatives and uses thereof
#498Peptide analogues with branched amino acid probe(s)
#499Monoclonal antibody FnAb8 and application thereof
#500Methods and compositions related to GPCR agonist polypeptides
#501METHOD FOR PREPARING SERMAGLUTIDE
#502Triple glucagon/GLP-1/GIP receptor agonist
#503Pro-drug peptide with improved pharmaceutical properties
#504Dipeptide comprising a non-proteogenic amino acid
#505MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
#506Pharmaceutical Compositions
#507PEPTIDE AGONISTS OF GLP-1 ACTIVITY
#508Glucagon analogues and methods of use
#509Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1
#510PEPTIDE THERAPEUTICS AND METHODS FOR USING SAME
#511Cysteine analogs of exendin-4
#512STABILIZED BIOACTIVE PEPTIDES AND METHODS OF IDENTIFICATION, SYNTHESIS, AND USE
#513Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
#514Glucagon-like-peptide-2 (GLP-2) analogues
#515Modified glucagon molecules
#516Peptide compound
#517Supramolecular modification of proteins
#518Insulin secreting polypeptides
#519GLP-1 derivatives and uses thereof
#520GIP peptide analogues
#521Double-acylated GLP-1 derivatives
#522Process for the preparation of liraglutide
#523Long-acting polypeptides and methods of producing and administering same
#524Double-acylated GLP-1 derivatives
#525Extended recombinant polypeptides and compositions comprising same
#526Composition for treating diabetes or diabesity comprising oxyntomodulin analog
#527FGF21 compound / GLP-1R agonist combinations with optimized activity ratio
#528GLP-1 and use thereof in compositions for treating metabolic diseases
#529Method of preparing physiologically active polypeptide conjugate
#530Pharmaceutical Composition Comprising a GLP-1 Agonist, an Insulin and Methionine
#531Insulin-incretin conjugates
#532Peptide pharmaceuticals for insulin resistance
#533EFFICIENT PRODUCTION OF PEPTIDES
#534Glucagon derivative and a composition comprising a long acting conjugate of the same
#535Exendin-4 derivatives as dual GLP1/glucagon agonists
#536Composition for treating hyperlipidemia comprising oxyntomodulin derivative
#537Protease-resistant lipidated GLP-1 analogs
#538Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
#539Compounds as peptidic GLP1/glucagon/GIP receptor agonists
#540Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists
#541Acylated glucagon analogues
#542Generating targeted sequence diversity in fusion proteins
#543Method of preparing glucagon-like peptide-2 (GLP-2) analog
#544ANALOGS OF GLUCAGON EXHIBITING GIP RECEPTOR ACTIVITY
#545GLUCAGON RECEPTOR AGONISTS
#546Acylated glucagon analogue
#547Long-lived polynucleotide molecules
#548Methods for labeling and manipulating a cellular circuit
#549Synthesis of GLP-1 Peptides
#550STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE
#551Pharmaceutical Composition
#552Acylated Glucagon Analogues
#553Fusion proteins of superfolder green fluorescent protein and use thereof
#554Liquid formulation of long acting insulinotropic peptide conjugate
#555Glucagon-receptor selective polypeptides and methods of use thereof
#556Glucagon derivatives
#557Stable pharmaceutical solution formulation of GLP-1R antibody fusion protein
#558Method of manufacturing an osmotic delivery device
#559Fusion polypeptide containing GLP and immunoglobulin hybrid Fc and use thereof
#560Polypeptide complex of titin-telethonin beta-pleated sheet structure as polypeptide drug carrier, method of using the polypeptide complex, and fusion protein complex thereof
#561Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
#562Co-agonists of the glucagon and GLP-1 receptors
#563Glucagon derivatives with improved stability
#564Glucagon/GLP-1 receptor co-agonists
#565Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
#566Glucagon/GLP-1 agonists for the treatment of obesity
#567Combination
#568Satiation peptides for weight loss and altered taste sensitivity
#569Alpha/beta-polypeptide analogs of glucagon-like peptide 1
#570GLP-1 derivatives and uses thereof
#571Branched discrete PEG constructs
#572Peptide-oligourea foldamer compounds and methods of their use
#573PROCESS FOR PREPARATION OF LIRAGLUTIDE
#574Incretin-insulin conjugates
#575Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
#576Propeptide-luciferase fusion proteins and methods of use thereof
#577Stabilized insulinotropic peptides and methods of use
#578Centrally-Acting Peptide Derivative, and Pharmaceutical Composition
#579Compositions, devices and methods of use thereof for the treatment of cancers
#580Peptide for treatment of type 2 diabetes mellitus and its complications
#581Protein and protein conjugate for diabetes treatment, and applications thereof
#582Elevated intracranial pressure treatment
#583Solid phase peptide synthesis
#584Functionalized Exendin-4 derivatives
#585Parenteral glucagon formulations
#586Oxyntomodulin analogs and methods of making and using same
#587Carrier immunoglobulins
#588Novel Glucagon Analogues
#589Transgenic pig islets and uses thereof for treating diabetes
#590Oxyntomodulin analogue
#591Multivalent heteromultimer scaffold design and constructs
#592Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteins
#593Dual cistronic bacterial expression system
#594Glucose-regulating polypeptides and methods of making and using same
#595GLP-1 derivatives
#596AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
#597GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
#598Methods of treatment using a pentapeptide derived from the C-Terminus of Glucagon-Like Peptide 1 (GLP-1)
#599METHOD FOR IMPROVING SOLUBILITY OF PROTEIN AND PEPTIDE BY USING IMMUNOGLOGULIN FC FRAGMENT LINKAGE
#600Exenatide analogue and use thereof